Arthritis, Musculoskeletal and Skin Diseases Research

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) funds research into arthritis, musculoskeletal, and skin diseases through CFDA 93.846, with the most recent grant award issued 4 months 3 days ago (February 20, 2027). The program maintains active grant-making cadence, though award volume has declined from 347 annually in 2023 to 189 in 2026, tracking a downward trend across the past five years.

The program funds basic and translational research addressing concrete disease mechanisms and therapeutic targets. Recent awards exemplify this scope: mechanisms of muscle atrophy in Duchenne muscular dystrophy using APE1/REF-1 inhibitors; genetic basis of osteoporosis through expression quantitative trait loci mapping and CRISPR validation; psychosocial factors and cardiovascular/renal outcomes in Black women with systemic lupus erythematosus; sweet taste receptor signaling in skeletal muscle proteostasis; molecular drivers of lupus nephritis; and mechanosensitive ion channels regulating skeletal muscle growth. Additional funded work spans tendon development and fibrotic adhesion formation, epidermal hypoxic priming and wound healing, wound healing neuronal control, osteoarthritis drug screening via click chemistry, and bone regeneration through hybrid tissue-engineered constructs. The portfolio emphasizes mechanism-focused investigation over descriptive epidemiology.

The program is predominantly Project Grants (95% of 15,351 total awards), with smaller shares of Block Grants (4%) and Cooperative Agreements (1%). Combined federal dollars obligated total $14.08 billion. The National Institute of Arthritis and Musculoskeletal and Skin Diseases itself accounts for 4,435 awards and $9.57 billion (approximately 68% of federal dollars), while the broader NIH (93.846 parent IC) provided 10,519 awards and $4.14 billion. The remaining share distributed across HHS, NIA, and OD represents subordinate contributions.

Recent award magnitudes range widely: predoctoral and postdoctoral fellowship stipends ($44–228 thousand), exploratory research R21 grants ($331–396 thousand), early-stage R43/R44 small-business innovation grants ($172–995 thousand), and established investigator R01 grants ($312–675 thousand). One notable mega-award funded a bioactive bone graft for large defect repair at $1.262 million.

Two recent opportunities remain open or forecasted: PAR-28-031 (NIAMS Clinical Trial Implementation Cooperative Agreement, posted June 10, 2026) solicits phased implementation grants for investigator-initiated clinical trials with completion of Phase 1 milestones required before transition to Phase 2; PAR-27-109 (Exploratory Clinical Trial Grants, posted June 10, 2026) targets proof-of-concept and Phase I/II trials in arthritis and musculoskeletal conditions, open to broad applicant categories. Both emphasize clinical translation and hypothesis-driven work aligned with NIAMS mission.

The program's funding base and award velocity support active pursuit for organizations with strong preliminary data and translational potential, particularly those positioned for Phase I/II clinical testing or mechanism-focused preclinical work addressing arthritis, bone, muscle, or skin disease.